The challenges of multiple drugs safety reporting
Pharmacovigilance of a single drug is one thing, but investigating an adverse event in case of polypharmacy is even more complex.
By
Abi Millar
Latest articles
All Articles
Ferring draws closer to a microbiome breakthrough
Ferring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.
By
Fighting India’s ‘black fungus’ epidemic
What exactly is black fungus, and what can be done to combat the rise of this condition alongside Covid-19?…
By
Blood plasma production: OK for the UK?
With the UK’s blood plasma donated ban lifted, Abi Millar looks into the risk-benefit analysis of producing plasma domestically.
By
Are competition authorities tightening the rules on pharma M&A?
The US Federal Trade Commission has initiated a multilateral working group to ensure that mergers and acquisitions in the…
By
Rewriting the pharma supply chain for a post-pandemic world
The pandemic has demonstrated the critical need for resilience and agility in pharma supply chains.
By
Academic-industry collaboration: how can licensing and partnerships be made smoother?
Abi Millar digs into academic-industry collaboration, and how this source of innovation could be better leveraged in the future.
By
Regenerative medicine: ready for the big leagues?
What is at the cutting-edge of regenerative medicine in 2021, and are these complex products ready to break into…
By
Antibiotic-adjacent: alternative approaches to tackling AMR
To combat the threat of antimicrobial resistance, researchers are testing alternatives to traditional antibiotics. Abi Millar explores innovative research…
By